Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10207709 | 1.00 | ARG1 (1.00) | ARG1ARG2 | |
| SCHEMBL895025 | 1.00 | ARG1 (1.00) | ARG1ARG2 | |
| SCHEMBL895311 | 0.99 | ARG1 (1.00) | ARG1ARG2 | |
| SCHEMBL20539769 | 0.99 | ARG1 (1.00) | ARG1ARG2 | |
| SCHEMBL895040 | 0.96 | ARG1 (0.94) | ARG1ARG2 | |
| SCHEMBL894843 | 0.94 | ARG1 (0.89) | ARG1ARG2 | |
| Hydrochloric Acid SCHEMBL894984 | 0.94 | ARG1 (0.92) | ARG1ARG2 | |
| Hydrochloric Acid SCHEMBL895176 | 0.93 | ARG1 (0.87) | ARG1ARG2 | |
| Hydrochloric Acid SCHEMBL895733 | 0.93 | ARG1 (0.89) | ARG1ARG2 | |
| SCHEMBL10006081 | 0.93 | ARG1 (0.89) | ARG1ARG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4659023-A1 | METHOD OF PREDICTING SUCCESS OF A CANCER THERAPY | Immusmol SAS (FR) | 2025-12-10 | — | — | EP | claimed |
| WO-2024161038-A1 | METHOD OF PREDICTING SUCCESS OF A CANCER THERAPY | IMMUSMOL SAS (FR) | 2024-08-08 | — | — | WO | claimed |
| EP-3696281-A1 | ARGINASE AS BIOMARKER AND DRUG TARGET FOR PCOS | Johann Wolfgang Goethe-Universität Frankfurt am Main (DE) | 2020-08-19 | — | — | EP | claimed |
| US-12569445-B2 | Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof | HALOZYME HYPERCON, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-12558323-B2 | Particle formation and morphology | ELEKTROFI, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20260049087-A1 | SOLID FORMS OF ISOQUINOLINONES, AND PROCESS OF MAKING, COMPOSITION COMPRISING, AND METHODS OF USING THE SAME | TWELVE THERAPEUTICS INC (US) | 2026-02-19 | — | — | US | disclosed |
| US-20260007615-A1 | PARTICLES COMPRISING A THERAPEUTIC OR DIAGNOSTIC AGENT AND SUSPENSIONS AND METHODS OF USE THEREOF | ELEKTROFI INC (US) | 2026-01-08 | — | — | US | disclosed |
| US-20260000616-A1 | METHODS OF FORMING PARTICLES BY CONTINUOUS DROPLET FORMATION AND DEHYDRATION | ELEKTROFI INC (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250383333-A1 | DETERMINATION OF PARTICULATE CONTAMINANTS IN PARTICLES AND COMPOSITIONS | ELEKTROFI INC (US) | 2025-12-18 | — | — | US | disclosed |
| EP-4659023-A1 | METHOD OF PREDICTING SUCCESS OF A CANCER THERAPY | Immusmol SAS (FR) | 2025-12-10 | — | — | EP | disclosed |
| US-12433849-B2 | Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof | ELEKTROFI, INC. (US) | 2025-10-07 | — | — | US | disclosed |
| US-20170088553-A1 | SOLID FORMS OF ISOQUINOLINONES, AND PROCESS OF MAKING, COMPOSITION COMPRISING, AND METHODS OF USING THE SAME | TWELVE THERAPEUTICS, INC. | 2017-03-30 | — | — | US | disclosed |
| US-20170087221-A1 | NITRIC OXIDE-MODULATING BONE-TARGETING COMPLEXES | ELWHA LLC | 2017-03-30 | — | — | US | disclosed |
| WO-2017048702-A1 | SOLID FORMS OF ISOQUINOLINONE DERIVATIVES, PROCESS OF MAKING, COMPOSITIONS COMPRISING, AND METHODS OF USING THE SAME | INFINITY PHARMACEUTICALS, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| WO-2016100619-A2 | TREATMENT AND DIAGNOSIS OF CANCER | RGENIX, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
| US-20150290207-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2015-10-15 | — | — | US | disclosed |
| US-9040703-B2 | Inhibitors of arginase and their therapeutic applications | MARS, INCORPORATED (US) | 2015-05-26 | — | — | US | disclosed |
| US-20140371175-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2014-12-18 | — | — | US | disclosed |
| US-20120083469-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2012-04-05 | — | — | US | disclosed |
| WO-2011133653-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED (US) | 2011-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260000616-A1 | METHODS OF FORMING PARTICLES BY CONTINUOUS DROPLET FORMATION AND DEHYDRATION | ALB, TNF, TTR | ARG1 2961/4885ARG2 3576/4885 |
| US-20170088553-A1 | SOLID FORMS OF ISOQUINOLINONES, AND PROCESS OF MAKING, COMPOSITION COMPRISING, AND METHODS OF USING THE SAME | PIK3CA, PIK3C2A, PIK3CD | ARG1 3774/4885ARG2 3537/4885 |
| US-12569445-B2 | Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof | ALB, S100P, S100A8 | ARG1 1839/4885ARG2 2268/4885 |
| US-12558323-B2 | Particle formation and morphology | CD63, EXOSC10, EPCAM | ARG1 488/4885ARG2 1858/4885 |
| US-20260049087-A1 | SOLID FORMS OF ISOQUINOLINONES, AND PROCESS OF MAKING, COMPOSITION COMPRISING, AND METHODS OF USING THE SAME | PRKCB, PRKCD, PRKCA | ARG1 1262/4885ARG2 1078/4885 |
| US-20260007615-A1 | PARTICLES COMPRISING A THERAPEUTIC OR DIAGNOSTIC AGENT AND SUSPENSIONS AND METHODS OF USE THEREOF | FLNB, FLNA, FUS | ARG1 2547/4885ARG2 2695/4885 |
| US-20150290207-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | ARG1 4077/4885ARG2 2115/4885 |
| US-20120083469-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | ARG1, ARG2, PRMT9 | ARG1 1/4885ARG2 2/4885 |
| US-20140371175-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | ARG1, ARG2, PRMT9 | ARG1 1/4885ARG2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.